周五盘中，Bio Rad实验室(BIO.N)股价大涨6.06%，主要受益于该公司公布的第一季度业绩超出市场预期。
根据公司发布的财报，截至3月31日的第一季度，Bio Rad实现调整后每股收益2.54美元，远高于分析师平均预期的1.81美元，也超过去年同期的2.29美元。尽管第一季度营收为5.854亿美元，同比下降4.2%，但仍高于分析师预期的5.7326亿美元。公司本季度净利润达到6400万美元。
面对这一亮眼业绩，多家投行调整了对Bio Rad的评级和目标价。花旗集团将该公司目标价从400美元下调至350美元，瑞银将目标价从355美元下调至310美元。尽管目标价有所下调，但分析师对该公司股票的平均评级仍维持在"买入"，其中4个"强烈买入"或"买入"评级，3个"持有"评级，没有"卖出"或"强烈卖出"评级。华尔街分析师对Bio Rad未来12个月的目标价中位数为367.50美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.